Announcing Ready Access to OM1 Registry Databases via BHE’s Instant Health Data (IHD) Platform [Press Release]

BHE is pleased to announce a new partnership with OM1 that facilitates the direct licensing of, and access to, OM1’s Disease Registry Databases via BHE’s market-leading real-world evidence (RWE) platform, Instant Health Data (IHD). OM1 maintains clinically rich longitudinal data in several chronic disease areas, including immunology.

OM1’s Rheumatoid Arthritis (RA) Registry Database is among the richest sources of commercially-available longitudinal RWE information for this condition, with detailed clinical measures assessed in real-world practice, linked with patient reported outcomes and medical and pharmacy claims data. This deep RA Registry includes longitudinal EMR, PRO, claims and other data on over 125,000 patients who are being actively followed across the United States.

These data are of interest for drug discovery, clinical trial planning, comparative effectiveness, treatment and outcomes assessment, market access and commercialization.

– Longitudinal data accumulated from 2013 through present
– Key outcome measures, such as laboratories, joint counts, PROs and disease activity measures, linked with pharmacy claims data
– Geographically and demographically representative of the RA population in the United States

In addition to the RA Registry, OM1 offers other rheumatology registries, such as SLE and ankylosing spondylitis, that may be accessed through IHD in the future. For more information about accessing the OM1 database in IHD, please contact your IHD account manager or reach out to jfuller@bhei.com.